YHB Investment Advisors Inc. Has $19.09 Million Holdings in Danaher Co. (NYSE:DHR)

YHB Investment Advisors Inc. trimmed its position in shares of Danaher Co. (NYSE:DHRFree Report) by 6.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 82,539 shares of the conglomerate’s stock after selling 6,082 shares during the period. Danaher accounts for approximately 1.8% of YHB Investment Advisors Inc.’s portfolio, making the stock its 12th largest holding. YHB Investment Advisors Inc.’s holdings in Danaher were worth $19,094,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after acquiring an additional 3,905,449 shares during the last quarter. Moneta Group Investment Advisors LLC raised its holdings in shares of Danaher by 96,490.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after buying an additional 23,262,904 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Danaher by 6.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock worth $2,030,327,000 after buying an additional 502,868 shares during the last quarter. Northern Trust Corp boosted its stake in Danaher by 1.7% in the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after buying an additional 134,905 shares in the last quarter. Finally, Norges Bank bought a new position in Danaher in the fourth quarter valued at about $2,057,164,000. 79.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the transaction, the director now owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock valued at $8,265,802 over the last ninety days. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

Shares of NYSE DHR opened at $239.95 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $177.69 billion, a PE ratio of 37.55, a PEG ratio of 3.65 and a beta of 0.83. The stock’s 50 day moving average price is $249.71 and its 200-day moving average price is $230.02. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business’s revenue was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.87 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 16.90%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DHR shares. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. JPMorgan Chase & Co. boosted their price target on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. KeyCorp raised their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, HSBC initiated coverage on shares of Danaher in a research report on Monday, December 18th. They set a “hold” rating for the company. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $267.43.

Check Out Our Latest Research Report on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.